Press Releases

Sign up for Email Alerts Press Release RSS

04/26/2018
Bristol-Myers Squibb Reports First Quarter Financial Results
Term:Corporate/Financial News
Language:English
04/25/2018
European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) Four-Week Dosing Schedule for Advanced Melanoma and Previously Treated Renal Cell Carcinoma
Term:Corporate/Financial News
Language:English
04/18/2018
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Patients with Small Cell Lung Cancer and Grants Priority Review
Term:Opdivo
Language:English
04/16/2018
Bristol-Myers Squibb Announces Worldwide Collaboration with Janssen to Develop and Commercialize Next-Generation Cardiovascular Therapy
Term:Partnering News
Language:English
04/16/2018
In CheckMate -141, Opdivo (nivolumab) Demonstrated Sustained Overall Survival (OS) Advantage over Standard of Care in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Term:Corporate/Financial News
Language:English
04/16/2018
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) Combination as First-Line Treatment for Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma
Term:Corporate/Financial News
Language:English
04/16/2018
Opdivo Plus Low-Dose Yervoy Combination Reduces the Risk of Progression or Death by 42% Versus Chemotherapy in First-Line Lung Cancer Patients with High Tumor Mutational Burden (TMB)
Term:Corporate/Financial News
Language:English
04/13/2018
Opdivo (nivolumab), First PD-1 Inhibitor to Demonstrate Superior Survival Benefit Compared with Chemotherapy in a Predominantly Chinese Population with Previously Treated Non-Small Cell Lung Cancer (NSCLC)
Term:Corporate/Financial News
Language:English
04/13/2018
Bristol-Myers Squibb and Illumina Announce Strategic Collaboration to Develop and Commercialize Companion Diagnostics for Bristol-Myers Squibb’s Oncology Immunotherapies
Term:Partnering News
Language:English
04/12/2018
Bristol-Myers Squibb and Harvard Announce New Fibrosis Research Collaboration
Term:$BMY
Language:English

Business Wire NewsHQ^sm